• Aucun résultat trouvé

Professional clinical guidelines for rare diseases: methodology

N/A
N/A
Protected

Academic year: 2021

Partager "Professional clinical guidelines for rare diseases: methodology"

Copied!
2
0
0

Texte intégral

(1)

HAL Id: inserm-00756021

https://www.hal.inserm.fr/inserm-00756021

Submitted on 22 Nov 2012

HAL is a multi-disciplinary open access

archive for the deposit and dissemination of

sci-entific research documents, whether they are

pub-lished or not. The documents may come from

teaching and research institutions in France or

abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est

destinée au dépôt et à la diffusion de documents

scientifiques de niveau recherche, publiés ou non,

émanant des établissements d’enseignement et de

recherche français ou étrangers, des laboratoires

publics ou privés.

Professional clinical guidelines for rare diseases:

methodology

Odile Kremp, Patrice Dosquet, Ana Rath

To cite this version:

Odile Kremp, Patrice Dosquet, Ana Rath. Professional clinical guidelines for rare diseases:

method-ology. From 6th European Conference on Rare Diseases and Orphan Products, May 2012, Brussels,

Belgium. pp.A12. �inserm-00756021�

(2)

M E E T I N G A B S T R A C T

Open Access

Professional clinical guidelines for rare diseases:

methodology

Odile Kremp

1*

, Patrice Dosquet

2

, Ana Rath

1

From 6th European Conference on Rare Diseases and Orphan Products

Brussels, Belgium. 23-25 May 2012

Guidelines are systematically developed statements to assist practitioner and patient decisions about appropri-ate health care for specific clinical circumstances [1]. They concern often complex diagnostic or therapeutic strategies with several possible interventions at each step, where each intervention has to be assessed and compared with other possible interventions at short and long term for efficacy, effectiveness, efficiency (optional), side effects, quality of life, acceptability, benefits/risks ratio. For common diseases, the methodology and the different steps of the guidelines development process have been established and apply the principles of evi-dence-based-medicine. Developing guidelines for rare diseases (RD) is more difficult, because of the lack of sound evidence, surveys of clinical practices, data about patients’ opinion and ethical reflexions [2].

During the 1st French national plan for rare diseases, HAS (French National Authority for Health) was mandated to define a method to develop guidelines for RD - which are called PNDS (National Diagnostic and Treat-ment Protocols) in France - and coordinate their writing with the RD centres of reference [3]. A PNDS constitutes a best practice reference document for healthcare profes-sionals in charge of rare disease patients. Based on it, HAS drawn up a “List of Procedures and Services” (LAP), which includes all of the diagnostic tests, drugs, medical devices and services that appear justified in providing care to a patient. From 2005 to now, only 47 PNDS were published and 8 are on-going, because the development method is complex and expertise is scarce; 135 new PNDS projects are pending. In the 2nd French plan for rare diseases it was proposed to define a simplified method for developing the PNDSs, in order to speed up their production, by using the protocols already developed by the RD reference

centres, incorporating and adapting recommendations devised by foreign groups of experts when appropriate; and setting criteria for prioritisation of the PNDS produc-tion. This process is on its way.

Orphanet has launched the production of emergency guidelines, written by centres of reference in collaboration with emergency department practitioners, patient organi-sations, and validated by a special reading group with members of emergency medicine learned societies. They include a short description of the disease, recommenda-tions for immediate care, transport and orientation, before getting to the emergency ward, recommendations for the emergency ward (complications to be looked for, diagnos-tic and therapeudiagnos-tic pardiagnos-ticularities, drugs interactions, anaesthesia), recommendations for patient’s and family’s comfort, list of contacts 24h/24 [4].

Author details

1

Orphanet, Inserm, Paris, France.2General Directorate for Health, Ministry of Health, Paris, France.

Published: 22 November 2012

References

1. Clinical Practice Guidelines: Directions for a New Program. [http://www. nap.edu/catalog.php?record_id=1626#toc]. 2. [https://www.iqwig.de/download/V10-01_Executive_Summary_Evidence_for_guidelines_on_rare_diseases.pdf]. 3. [http://www.has-sante.fr/portail/jcms/c_435989/methode-d-elaboration-du- protocole-national-de-diagnostic-et-de-soins-et-de-la-liste-des-actes-et-prestations-par-le-centre-de-reference-d-une-maladie-rare?xtmc=&xtcr=1]. 4. [http://www.orpha.net/consor/www/cgi-bin/Disease_Emergency.php? lng=FR]. doi:10.1186/1750-1172-7-S2-A12

Cite this article as: Kremp et al.: Professional clinical guidelines for rare diseases: methodology. Orphanet Journal of Rare Diseases 2012 7(Suppl 2): A12.

* Correspondence: odile.kremp@inserm.fr

1Orphanet, Inserm, Paris, France

Full list of author information is available at the end of the article Kremp et al. Orphanet Journal of Rare Diseases 2012, 7(Suppl 2):A12 http://www.ojrd.com/content/7/S2/A12

© 2012 Kremp et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Références

Documents relatifs

Higher adherence to French dietary guidelines and chronic diseases in the prospective SU.VI.MAX cohort: Diet quality and chronic diseases... Abstract

4 Département d’Etudes Cognitives, École normale supérieure, PSL University, Paris, France, 5 Inserm U955, Institut Mondor de Recherche Biomédicale, Equipe E01

▪EU Council Conclusions for COP-14 : referts to « targets that are ambitious, realistic, and as far as possible, measurable and time-bound, strengthening and building upon the

In view of this, a policy framework intended to fairly evaluate these drugs was devel- oped by the Drugs for Rare Diseases Working Group (DRDWG) at the request of the Ontario

Patients were excluded if they had an unstable cardiac condition (defined as: unstable angina pectoris, acute heart failure, significant cardiac arrhythmias, symptomatic

P In all the algorithms, during the course of UC, when the first course of anti-TNF has therapy has failed: in the absence of PK dosing, in a patient presenting with a primary

The devel- opment of national guidelines on preconception care would draw attention to the schisms in our health sys- tem—between women’s health care and neonatal care, and

After the launch of the French Reference Centre for Rare Lung Diseases (RespiRare W ), we created a national network and a web-linked database to collect data on pediatric